- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Early Findings of the Oncology Patient-Centered Medical Home
One of the early findings from various oncology medical homes throughout the country was that they work, claimed Ted Okon, BS, MBA, executive director of the Coalition Oncology Alliance.
%jwplayer%
One of the early findings from various oncology medical homes throughout the country was that they work, claimed Ted Okon, BS, MBA, executive director of the Coalition Oncology Alliance.
The importance of oncology medical homes is that they ensure quality and affordable care for patients.
“It’s about patients; it’s not about anything else,” he said. “It’s about patient care.”
Successful oncology medical homes have been putting in the work to lower emergency room and hospital utilization and improving adherence with advanced care planning and directives. Timely feedback that allows practices to benchmark themselves against one another is incredibly important, Mr Okon said.
“If providers and payers don’t come together for one reason—patients—then the bottom line is we will fail and fail miserably and cost will increase,” he said.
However, despite these accomplishments, Mr Okon emphasized that payers and providers all agree: becoming a successful oncology medical home requires a lot of work.
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More
